mTOR inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 7, 2014, Pages

  Plantinga, Theo S ^a   Heinhuis, Bas ^a   Gerrits, Danny ^a   Netea, Mihai G ^a   Joosten, Leo A B ^a   Hermus, Ad R M M ^a   Oyen, Wim J G ^a   Schweppe, Rebecca E ^b   Haugen, Bryan R ^b   Boerman, Otto C ^a   Smit, Johannes W A ^a   Netea Maier, Romana T ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; SMALL INTERFERING RNA; SODIUM IODIDE SYMPORTER; THYROID TRANSCRIPTION FACTOR 1;

ARTICLE; AUTOPHAGY; BC PAP CELL LINE; CARCINOMA CELL LINE; CELL DIFFERENTIATION; ENZYME INHIBITION; FTC133 CELL LINE; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; IODINE UPTAKE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; THYROID CARCINOMA; TPC1 CELL LINE; TRANSPORT AT THE CELLULAR LEVEL; UPREGULATION;

AUTOPHAGY; CARCINOMA, PAPILLARY, FOLLICULAR; CELL DIFFERENTIATION; CELL LINE, TUMOR; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; INTERLEUKIN-6; IODINE RADIOISOTOPES; SIROLIMUS; THYROID NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 84904045078     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-1171     Document Type: Article

References (42)

1. Schlumberger M. Target therapies for radioiodine refractory advanced thyroid tumors. J Endocrinol Invest. 2012;35:40-44.
2. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13:184-199.
3. Durante C, Puxeddu E, Ferretti E, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab. 2007;92:2840-2843. (Pubitemid 47037399)
4. Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M, Santisteban P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer. 2006;13:257-269.
5. Henderson YC, Shellenberger TD, Williams MD, et al. High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res. 2009;15:485-491.
6. Kogai T, Sajid-Crockett S, Newmarch LS, Liu YY, Brent GA. Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells. J Endocrinol. 2008;199:243-252.
7. Malehmir M, Haghpanah V, Larijani B, et al. Multifaceted suppression of aggressive behavior of thyroid carcinoma by all-trans retinoic acid induced re-differentiation. Mol Cell Endocrinol. 2012;348:260-269.
8. Coelho SM, Vaisman F, Buescu A, Mello RC, Carvalho DP, Vaisman M. Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma. Braz J Med Biol Res. 2011;44:73-77.
9. Fernandez CA, Puig-Domingo M, Lomena F, et al. Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptake. J Endocrinol Invest. 2009;32:228-233.
10. Zhang M, Guo R, Xu H, Zhang M, Li B. Retinoic acid and tributyrin induce in vitro radioiodine uptake and inhibition of cell proliferation in a poorly differentiated follicular thyroid carcinoma. Nucl Med Commun. 2011;32:605-610.
11. Yuan GB, Kuang AR, Fan Q, Yu LB, Mi YX. Combined effects of all-trans-retinoic acid and trichostatin A on the induction of differentiation of thyroid carcinoma cells. Chin J Cancer. 2010;29:379-384.
12. Vivaldi A, Miasaki FY, Ciampi R, et al. Re-differentiation of thyroid carcinoma cell lines treated with 5-aza-2′-deoxycytidine and retinoic acid. Mol Cell Endocrinol. 2009;307:142-148.
13. Beyer S, Lakshmanan A, Liu YY, et al. KT5823 differentially modulates sodium iodide symporter expression, activity, and glycosylation between thyroid and breast cancer cells. Endocrinology. 2011;152:782-792.
14. Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013;368:623-632.
15. Kim K, Cabanillas M, Lazar AJ, et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring V600EBRAF mutation. Thyroid. 2013;23(10):1277-1283.
16. Liu D, Hu S, Hou P, Jiang D, Condouris S, Xing M. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res. 2007;13:1341-1349. (Pubitemid 46424076)
17. Hou P, Bojdani E, Xing M. Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways. J Clin Endocrinol Metab. 2010;95:820-828.
18. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274-293.
19. de Souza EC, Padron AS, Braga WM, et al. mTOR downregulates iodide uptake in thyrocytes. J Endocrinol. 2010;206:113-120.
20. Faustino A, Couto JP, Populo H, et al. mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012;97:E1139-E1149.
21. Molina AM, Feldman DR, Voss MH, et al. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2012;118:1868-1876.
22. Ansell SM, Tang H, Kurtin PJ, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol. 2011;12:361-368.
23. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514-523.
24. Dazert E, Hall MN. mTOR signaling in disease. Curr Opin Cell Biol. 2011;23:744-755.
25. Huijbers A, Plantinga TS, Joosten LA, et al. The effect of the ATG16L1Thr300Ala polymorphism on susceptibility and outcome of patients with epithelial cell-derived thyroid carcinoma. Endocr Relat Cancer. 2012;19:L15-L18.
26. Plantinga TS, Crisan TO, Oosting M, et al. Crohn's disease-associated ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon activation of NOD2. Gut. 2011;60:1229-1235.
27. Knauf JA, Kuroda H, Basu S, Fagin JA. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene. 2003;22:4406-4412. (Pubitemid 36897971)
28. Maximo V, Lima J, Prazeres H, Soares P, Sobrinho-Simoes M. The biology and the genetics of Hurthle cell tumors of the thyroid. Endocr Relat Cancer. 2012;19:R131-R147.
29. Schweppe RE, Klopper JP, Pugazhenthi U, et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab. 2008;93:4331-4341. (Pubitemid 352789529)
30. Levy O, Dai G, Riedel C, et al. Characterization of the thyroid Na+/I- symporter with an anti-COOH terminus antibody. Proc Natl Acad Sci USA. 1997;94:5568-5573. (Pubitemid 27241810)
31. Dohan O, Paroder V, Riedel C, et al. The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr Rev. 2003;24:48-77. (Pubitemid 36223279)
32. Tsuyuki S, Takabayashi M, Kawazu M, et al. Detection of mRNA as an indicator of autophagosome formation. Autophagy. 2014;10(3):497-513.
33. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW. Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab. 2009;94:4107-4112.
34. Sugino K, Ito K, Mimura T, Kameyama K, Iwasaki H, Ito K. Hurthle cell tumor of the thyroid: analysis of 188 cases. World J Surg. 2001;25:1160-1163. (Pubitemid 32845829)
35. McDonald MP, Sanders LE, Silverman ML, Chan HS, Buyske J. Hurthle cell carcinoma of the thyroid gland: prognostic factors and results of surgical treatment. Surgery. 1996;120:1000-1004.
36. O'Reilly T, McSheehy PM, Kawai R, et al. Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents. Cancer Chemother Pharmacol. 2010;65:625-639.
37. Napoli KL, Wang ME, Stepkowski SM, Kahan BD. Distribution of sirolimus in rat tissue. Clin Biochem. 1997;30:135-142. (Pubitemid 27180926)
38. Brewer C, Yeager N, Di Cristifano A. Thyroid-stimulating hormone initiated proliferative signals converge in vivo on the mTOR kinase without activating AKT. Cancer Res. 2007;67:8002-8006. (Pubitemid 47395133)
39. Ohmori M, Endo T, Harii N, Onaya T. A novel thyroid transcription factor is essential for thyrotropin-induced up-regulation of Na+/I- symporter gene expression. Mol Endocrinol. 1998;12:727-736. (Pubitemid 30659074)
40. Damante G, Di Lauro R. Thyroid-specific gene expression. Biochim Biophys Acta. 1994;1218:255-266. (Pubitemid 24252520)
41. Boggaram V. Thyroid transcription factor-1 (TTF-1/Nkx2.1/TITF1) gene regulation in the lung. Clin Sci (Lond). 2009;116:27-35.
42. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer. 2006;6:292-306.